Welcome

The EUROPEAN STATISTICAL FORUM is pleased to announce its 3rd Annual Conference:

Advancing adaptive designs for the identifications
of subpopulations and the new frontiers of benefit
risk assessment

Monday, 19th November 2012
Hotel Palace Berlin
Budapester Straβe 45, Berlin, Germany
8:45 am – 5:00 pm  GMT+1

The third edition of the European Statistical Forum is dedicated to explore and understand two of the new key challenges for drug development:

       • the detection of subpopulations with the highest treatment response and
       • the benefit-risk ratio requirement and methodologies with a particular focus 
         to the submission process.

The current advances in molecular profiling and genomic biomarkers provide new challenges for clinical trials design and statistical analysis. The conference will provide insights on adaptive designs for population enrichment and subgroup selection and may provide powerful tools for the identification of biomarkers predictive of treatment benefit in order to apply this knowledge to better treat patients in the future.

Positive phase III trials are no longer a guarantee for the approval of a new compound. Risk-benefit assessments are getting more and more important for a successful registration as well as reimbursement, increasing the still high attrition rate for new therapeutics. The conference will explore this key area of clinical trial development by bringing together experts in the fields.

Specific attention will be deserved to the most advanced methodological, operational and regulatory characteristics of these two key aspects of drug development.

Sunday, 18th November, 7:30 pm
Exclusive VIP Dinner, for more information click here >>